Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exonic variants in multiple myeloma patients associated with relapsed/ refractory and response to bortezomib regimens

15 Sept 2021

Abstract excerpt

Novel treatment in multiple myeloma represented by proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies have produced a deep response. However, relapses are possible, and all classes of drugs are refractory to patients. Next-generation sequencing has improved our understanding of the multiple myeloma genome related to drug resistance and has discovered many genomic variants. Therefore, this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glycosylation and Glycoproteins Research
Share to Multiple Myeloma Research and Treatments
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35002457
DOI: 10.1016/j.sjbs.2021.09.017

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exonic variants in multiple myeloma patients associated with relapsed/ refractory and response to bortezomib regimensPMID 35002457Read ↗

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myelomaSemantic proximity Read ↗

Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myelomaSemantic proximity Read ↗

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myelomaSemantic proximity Read ↗

Gene mutations in newly diagnosed multiple myeloma patients detected by next-generation sequencing technologySemantic proximity Read ↗

Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities.Semantic proximity Read ↗

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.Semantic proximity Read ↗

Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myelomaSemantic proximity Read ↗

Multi-omics analysis of multiple myeloma patients with differential response to first-line treatment.Semantic proximity Read ↗

Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathwaysSemantic proximity Read ↗

Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myelomaSemantic proximity Read ↗

MyeloDB: A multi-omics resource for Multiple MyelomaSemantic proximity Read ↗

A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.